Anavex Life Sciences Corp (AVXL)

[sokol]

Assuming the science behind Anavex's drug development is legitimate and worthy of exploring, as many do. Access to capital to do that is critical, and “access to reasonably priced capital” is better as I think Froll understands better than I. Access to capital supposedly has been a problem for emerging biotechs all along. See this:

Emerging Biotechs’ Greatest Challenge: Acquiring Capital

"Biotechnology companies heard a clear message at the 12th annual Biotech Investment Conference, in Millbrae, Calif.: To get cash, you need a good management team to get a product to market. Acquiring capital is the major challenge emerging biotechs face. And, without products to sell, there are limited ways to obtain capital, making the task daunting."

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564327/

So, I am open to trying to understand what, if any, well-meaning concerns there may be to the steps that Anavex has taken to obtain the capital necessary to the development of its drug or drugs that may be of great benefit to society. Moreover, if well-founded worry or unease exists, I think it should be in terms that are meaningful and understandable. After all, we discuss a drug or drugs that may affect the lives of human beings with dreaded and fatal consequences—their lives matter.